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Abstract 
Background. Cognitive Behavioural Therapy (CBT) is the first-choice treatment in the ultra-high risk 
(UHR) for psychosis group. However, CBT is an umbrella term for a plethora of different strategies, 
and little is known about the dosing or content of CBT and symptomatic outcome. The current study 
aims to characterise a cognitive-behavioural case management (CBCM) regimen in UHR. Specifically, 
we examine the association between session dosing, CBCM content and the course of depressive 
(DS) and attenuated psychotic symptomatology (APS).  
Methods. A sample of 242 UHR participants received 6 months of CBCM in the context of the multi-
centre Neurapro trial with monthly assessments of symptomatology. Using multilevel regressions, 
the association between CBCM dose, content and symptomatology over four months follow-up (M1-
M4) were investigated.  
Results. In M1, higher session dose and symptom assessment predicted increased APS but 
decreased DS. In M3, higher session dose predicted a decrease in APS. More focus on positive 
symptoms and symptom assessment predicted decreased DS, while more focus on stress 
management and negative symptoms predicted increased DS overall.  
 Conclusion Our findings indicate that the association between dose/content of CBCM and level of 
symptomatology in a sample of UHR participants depends on time in treatment and varies for DS 
and APS. CBCM may positively impact depressive symptoms in the beginning of treatment, while 
APS may be positively impacted only later in the course of treatment. Therefore, it seems important 
to keep UHR young people engaged in treatment beyond this initial period.  
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Introduction  
The at-risk-mental state or ultra-high risk (UHR) state describes individuals identified as being at 
enhanced risk of developing a first episode of psychosis, based on the presence of attenuated/short 
lived psychotic symptoms or a significant drop in functioning in the context of a family history of 
psychosis. Since the introduction of the UHR criteria[1], considerable research attention has been 
directed towards the development of effective interventions to positively impact on the trajectory of 
the UHR state. Growing evidence suggests that psychological therapies such as cognitive-behavioural 
therapy (CBT) may provide a safe and effective pre-emptive treatment option in UHR clients [2-7]. 
While recent studies suggest that both psychological and pharmacological interventions reduce rates 
of transition to psychosis, CBT is, given the favourable risk benefit ratio, considered first choice 
treatment in UHR groups [8, 9].  
 
CBT-informed therapy is an umbrella term for a plethora of different strategies that has primarily 
been evaluated as an overall ‘treatment package’[10] which, in clinical implementation, is carried 
out in a variety of forms[11, 12]. CBT comprises various components such as psychoeducation, case 
formulation, cognitive challenging, or behavioural strategies. Little is known, especially in the field of 
at-risk mental states, about which components of CBT are in fact delivered and if there are specific 
CBT ‘ingredients’ which may be more beneficial than others[10, 13]. Furthermore, the effects of 
frequency or dosing of CBT (i.e., number of sessions delivered) on treatment outcome has only been 
partially investigated[4]. The United Kingdom-based EDIE-2 trial showed that a higher number of 
sessions was associated with less attenuated psychotic symptoms at 12-month follow up [4]. 
Secondary analyses based on this trial evaluated the presence of certain components in cognitive 
therapy from file notes and identified a greater treatment effect if case formulation and homework 
were part of the therapy [13]. Another study in clients with psychosis suggested that CBT was only 
beneficial for those who received the full nine months of CBT. CBT exclusively consisting of 
engagement or assessment was not effective, and the therapy appeared to have a detrimental effect 
on those who did not finish the intervention [10]. 
Although there is evidence for an early (first four weeks) rapid response to CBT for depression [14, 
15], little is known regarding the role of time in treatment in the UHR population. A qualitative study 
in psychosis investigating clients’ experiences of case formulation in CBT suggested that the reaction 
may be subject to change over time: some clients experienced it initially as confrontational, however 
this improved over time in most clients [16]. 
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The current study addresses the need to identify effective components of CBT-informed therapy in 
UHR clients. This may help to develop more targeted and more effective treatment packages for 
future studies and clinical implementation.   
In the present study, a UHR treatment regimen consisting of CBT delivered within a therapeutic case 
management framework (CBCM) was evaluated. In CBCM, the case manager is a central clinician 
who both manages general aspects of the patient’s care and provides psychotherapy.  
The aims of the present study were to (1) characterise the CBCM provided in this study and (2) 
investigate if dosing of CBCM and/or specific CBCM components received predicted the level of 
attenuated psychotic symptoms (APS) and depressive symptoms at follow-up assessments.  
Based on existing literature, it was hypothesised that a greater number of sessions would be 
associated with lower levels of symptomatology at follow-up assessments. Exploratory analyses 
regarding the specific CBCM components and time into treatment were also conducted.  
 
Method  
Study design and setting 
This study is based on data from the Neurapro trial, a multi-centre randomized controlled trial 
investigating the effects of omega-3 polyunsaturated fatty acids (PUFA) versus placebo in UHR 
individuals (ACTRN 12608000475347)[14, 15]. Overall, 304 participants aged 13-40 years and 
meeting criteria for UHR status received either omega-3 PUFA together with CBCM, or placebo with 
CBCM. The total study period was 12 months. All participants provided written informed consent 
prior to enrolment to the study. Details on study methodology and RCT results have been described 
in detail previously[14, 15]. No significant differences in demographic characteristics, clinical, 
functional outcomes or CBCM were observed between the experimental and control groups[15], 
therefore CBCM across both groups was used for analysis in the current study.  
 
Cognitive-Behavioural Case Management 
All participants received CBCM adapted to the participant’s level of need and symptom profile within 
the first six months (M0 [baseline] to M6) of study enrolment (longer if indicated), with monthly 
research visits assessing symptomatic outcome. All clinicians were trained according to a study-
specific CBCM manual prior to study start. The manual consist of the following modules: (1) stress 
management, (2) positive symptoms, (3) negative symptoms, (4) basic symptoms, (5) comorbidity. 
Session dates and CBCM content were recorded using a checklist completed by the clinician after 
every CBCM session. The checklist was divided into 13 CBCM components (see Table 1, first column) 
and an open field was provided for additional written information describing the content of the 
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session. The content of this open field was reviewed by two authors (JAH and BN) and consensus 
was reached as to component categorisation.  
Since participants received on average less than one CBCM session in M5 and M6, and 80% of the 
sessions within the 6-month CBCM period occurred during the first four months, the current 
investigation focused on these first four months (M0-M4) of CBCM. 
Session information was assigned to one of four follow-up intervals based on the date of each 
session, separately for each individual. Sessions occurring between assessments M0 and M1, M1 and 
M2, M2 and M3, M3 and M4 were assigned to interval 1, 2, 3 and 4, respectively (see Figure 1 for an 
overview). The following variables were created per individual per interval: Number of sessions 
received (0, 1, 2, 3, 4 or more) and number of times each specific component was received.  
 
Outcome Measures 
Level of attenuated psychotic symptoms (APS) was operationalised using the procedure described in 
Morrison et al.[4]: Using the Comprehensive Assessment of At-Risk Mental States (CAARMS[16]), we 
summed the scores of the product of global rating scale score (0-6) and frequency (0-6) of the four 
subscales unusual thought content, non-bizarre ideas, perceptual abnormalities, and disorganised 
speech. Severity of depressive symptoms was assessed using the Montgomery-Asberg Depression 
Scale (MADRS[17]). 
 
Statistical Analyses  
Due to the hierarchical structure of the data (repeated measures (level 1) nested within participants 
(level 2), and participants nested within study sites (level 3)), analysis were conducted using the 
procedure ‘mixed’ for STATA 14.0 for linear mixed models, bootstrapped with 500 replications.  
We conducted a sensitivity analysis including completers only (i.e., participants who completed all 
symptom assessments). Furthermore, as putting a lagged response variable into a mixed model may 
yield biased results due to the correlation of the lagged variable with the combined error term 
(‘incidental parameter problem’), we replicated the initial analysis (number of sessions, see below) 
using the recently formulated STATA command ‘xtdpdml’, which addresses this problem using 
maximum likelihood estimation with structural equation modelling (as described by Allison and 
colleagues[18]).  
 
Number of sessions  
To investigate the association between number of sessions received and level of severity of APS, we 
applied the procedure of autoregressive lagged modelling as described in Zilcha-Mano et al[19]. 
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Number of sessions was regressed on APS, while controlling for previous symptomatic levels (APS (T-
1), see Figure 1.) Additionally, we controlled for MADRS scores (depressive symptoms), gender, age, 
number of sessions already received and number of days within that interval. As the association 
between number of sessions received and APS may depend on time in treatment, an interaction 
term between number of sessions (continuous) and assessment time point (categorical, M1-M4) was 
introduced [19]. Interaction terms were removed when not significant. For depressive symptoms, 
number of sessions were regressed on MADRS scores, while controlling for previous MADRS score (T-
1) and APS (remainder as for APS model).  
 
CBCM components  
The same model as described above was applied to investigate the association between specific 
CBCM components (number of times each component received) and symptomatic levels (APS and 
MADRS scores).  
Components that may be related to outcome were initially identified in a lagged regression model 
unadjusted for the other components. Components which constituted more than 15% of the 
sessions (see Table 1) and with significant associations were included in the full model, which was 
adjusted for all other components. For APS as outcome, full model components included case 
management, monitoring, assessment of symptoms, stress management, positive symptoms, and 
homework. For MADRS as outcome, full model components included monitoring, assessment of 
symptoms, stress management, positive symptoms, negative symptoms, basic symptoms and 
homework. As the association between CBCM component and APS/MADRS may depend on time in 
treatment, an interaction term between component and time point (M1-M4) was introduced [19]. 
Interaction terms were removed when not significant. We used the same autoregressive lagged 
modelling structure: we controlled for previous symptoms, while adjusting for gender, age, number 
of sessions received and number of days within each interval. As not all CBCM components were 
received by all participants, each model only included those participants who received the 
component at least once.  
As this study aimed to identify effective intervention elements, participants who transitioned to first-
episode psychosis during follow-up were excluded from analyses.  
 
Results  
Of the 304 participants randomized in the parent study[15], 268 participants (88%) had at least one 
symptom assessment other than baseline with CBCM checklist data on at least one session available. 
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Twenty-six participants (9%) were excluded because they transitioned to a full psychotic episode 
during follow-up. Thus, a total of 242 participants (80%) were included in analyses.   
Table 2 displays baseline demographic and clinical information. Participants received on average a 
total of 10.4 sessions (SD 5.83, Range 1-32). The number of sessions per month significantly 
decreased over time (p<.001). The most prevalent CBCM components administered were 
monitoring, stress management and assessment of symptoms (Table 1). The proportion of the 
components general information/psychoeducation, monitoring, assessment of symptoms, positive 
symptoms, basic symptoms, and homework decreased over time (p<.01). The proportion of relapse 
prevention and termination increased with time (p<.001). All other components remained stable.  
 
Number of sessions and symptomatic outcome 
In predicting the level of APS, the overall interaction between number of sessions and assessment 
time point was significant (χ2(3) = 19.61, p<.001). Using Stata’s procedure MARGINS, the slopes per 
time point were subsequently estimated. For M1, there was a significant positive association 
between number of sessions and level of APS (i.e., more sessions significantly predicted higher level 
of APS at the end of M1: b = 2.01, SE = .67, p = .003, 95% CI [.69,3.33]; Figure 2) while by M3, a 
significant negative association between number of sessions and the level of APS was observed (i.e., 
more sessions significantly predicted a lower level of APS: b = -1.29, SE = .45, p=.004, 95% CI [-2.17,-
.41]; Figure 2). Sensitivity analyses using completers only (n=188) and the xtdpdml procedure yielded 
similar results: a positive association between number of sessions and APS in M1, and a negative 
association for M2-M4 (see S1).  
In predicting the MADRS scores, there was an overall interaction between number of sessions and 
time point (χ2(3) = 12.59, p = .006). Using Stata’s procedure MARGINS, the slopes per time point 
were subsequently estimated. There was a significant negative association between number of 
sessions and MADRS at M1 (i.e., more sessions significantly predicted lower levels of depressive 
symptoms at the end of M1: b=-.89, SE=.34, p=.009). However, no significant association was 
observed for the other months (p values between .123 and .965). Sensitivity analyses including 
completers only and the xtdpdml procedure yielded a similar pattern: a negative association 
between number of sessions and depressive symptoms in M1, and no association in M2-M4 (see S1). 
 
CBCM Components and symptomatic outcome 
Family work, crisis management, and relapse prevention/termination were a priori excluded from 
analyses because these components constituted less than 15% of the CBCM sessions (see Table 1).  
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Table 3 provides the results of the full models. For APS levels, most components showed an 
interaction with time, with a similar pattern to that seen for number of sessions. There was a 
positive association between the CBCM component assessment of symptoms and level of APS during 
the first month. For the components case management, monitoring, and stress management, a 
negative association was observed from M2 or M3, which approaches significance in M3.  
For the MADRS scores, the components did not yield an interaction with time, but a negative 
main effect for the components assessment of symptoms and positive symptoms (i.e. more 
assessment of symptoms/focus on positive symptoms predicted less depressive symptoms overall), 
and a positive main effect for stress management and negative symptoms were observed.  
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Discussion 
Our study investigated the content and dosing of a CBCM regimen in UHR participants provided in 
the context of the Neurapro trial, both descriptively as well as in association with level of depressive 
and attenuated psychotic symptomatology. Our findings indicate that the majority of CBCM 
occurred within the first four months of the protocol and there was substantial variation in the 
number of sessions received (ranging from 1 to 32 sessions), likely reflecting variation in clients’ level 
of engagement with the psychosocial aspect of intervention provided during the trial. The most 
frequently delivered elements of CBCM were monitoring, stress management and assessment of 
symptoms.  
In this study, we found that a greater number of sessions predicted an increased level of APS at the 
end of the first four weeks of treatment, an association which was reversed by M3 (i.e. more 
sessions was associated with a decrease in APS). To our knowledge, our findings are the first to 
indicate that the association between ‘dosing’ of CBCM (i.e., number of sessions received) and level 
of APS may depend on time in treatment. These results appear to be robust as the same pattern was 
observed when two separate sensitivity approaches were applied.  
These novel findings may be interpreted in several ways. First of all, it is possible that the early, 
‘unfavourable’ CBCM-APS association is related to a form of response bias. At the beginning of the 
treatment, the amount of psychoeducation regarding UHR is high, potentially leading to a change in 
how and what experiences are revealed compared to the initial assessment. In other words, 
participants may be better informed, better able to describe, and potentially reveal new experiences 
they did not at the initial assessment, leading to a higher rating of APS on the CAARMS for those who 
received more CBCM sessions. Alternatively, the positive association between number of sessions 
and level of APS in the first four weeks may be driven by participants with increasing APS receiving 
more sessions, i.e., an increase in clinical contact in response to worsening symptoms. Similarly, the 
negative association between number of sessions and APS in M3 may be driven by participants with 
decreasing APS receiving less sessions. However, the probability of this form of reverse causation 
has been reduced by controlling for the previous level of APS for every participant.  
Conversely, and speculatively, it may be the case that at the very outset of treatment, CBCM leads to 
an initial intensification of APS. In support of this, Dunn et al.[10] identified a potential negative 
effect of CBT in patients with psychosis who stopped the treatment prematurely. Furthermore, a 
qualitative study on clients’ experience of CBT’s case formulation suggested a change over time with 
some clients experiencing it as confrontational in the beginning, but with an improvement of those 
feelings over time in most clients[20]. Another qualitative study investigating the subjective 
experiences of UHR participants of the EDIE-2 trial indicated that many clients disclosed their 
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unusual psychological experiences for the first time in their lives[21]. Clients also suggested that 
talking about these experiences was challenging or difficult[20, 21]. It is conceivable that initial 
confrontation with these unusual experiences at the beginning of CBCM treatment is responsible for 
the initial increase in reported APS. This is speculative and our results need to be replicated before 
firm conclusions can be drawn. It may reflect some traditional views of psychotherapy for 
psychosis[10, 22]: Talking about the content of psychotic experiences was sometimes discouraged 
from this perspective as it could lead to an aggravation or ‘inadvertent collusion’[23]. Most 
importantly, however, our results suggest that participants may start to benefit from more sessions 
of CBCM when they continue treatment.  
A change in therapeutic alliance may also play a role in the observed association between CBCM 
dosing and APS. Therapeutic alliance is defined as the quality of the relationship between client and 
therapist and is regarded to play a pivotal role in the outcome of psychotherapy[24]. In a sample of 
people with acute first- or second-episode psychosis, Goldsmith et al.[22] showed that CBT may 
have detrimental effects (i.e. worse symptomatic outcome) when the therapeutic alliance is poor, 
and positive effects when the alliance is good. More importantly, improving the therapeutic alliance 
was associated with enhanced outcome[22]. In the current study, the changing association between 
CBCM dosing and APS may be a result of an improving therapeutic alliance over time. 
For the CBCM components, we observed a similar pattern as for the dosing: when a specific 
component predicted decreased APS, this occurred in M3 (however, associations began to change 
from positive to negative in M2); and if a specific component predicted increased symptoms, this 
occurred in the first four weeks. Assessment of symptoms was positively associated with level of 
reported APS at the end of M1. This is in line with the previous speculations on (1) disclosing APS for 
the first time, (2) becoming more knowledgeable about APS symptoms. It is consistent with a study 
by Dunn et al. in patients with psychosis which indicated that CBT merely consisting of assessment 
and engagement was not beneficial[10] and the well-known phenomenon of psychotic clients being 
guarded about their symptoms early on[25]. 
The association between CBCM and depressive symptomatology seemed to follow a different 
pattern than for APS. In the case of depression, a higher number of sessions predicted less 
depressive symptoms in the first four weeks, after which no association between dosing of CBCM 
and level of depressive symptoms was observed. This finding is in line with the well-known and long-
established ‘early rapid response’ to CBT in depression[26-28], which has demonstrated that most 
change occurs in the first four weeks of CBT, after which time the response flattens. It has been 
argued that this response is due to nonspecific factors such as an amelioration of the hopelessness 
factor of depression at the beginning of treatment, rather than CBT-specific factors such as cognitive 
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restructuring or behavioural activation[27]. Alternatively, the association between CBT and 
depressive symptoms in the first four weeks may be driven by participants with decreasing 
depressive symptoms receiving less sessions because they are already responding, although the 
plausibility of this explanation is reduced in the current analysis by our statistical approach (please 
see above).  
Regarding the specific components, results showed an interesting contrast to APS. The assessment 
of symptoms component predicted less depressive symptoms. In contrast to APS, reporting 
symptoms may be associated with a form of relief as reflected in less depressive symptoms, 
especially at the start of the treatment. A similar interpretation is conceivable for the finding that a 
focus on positive symptoms predicted less depressive symptoms. In other words, disclosing and 
working on one’s attenuated psychotic experiences may not be associated with a decrease in 
intensity or frequency of those experiences, but with a decreased overall affective response.  
Unexpectedly, stress management and negative symptoms seemed to predict overall more 
depressive symptoms. A number of different explanations of this finding are possible. First, in 
contrast to level of APS, which showed a negative association with stress management in M3 (i.e., 
more stress management, less APS), the management of stress consisting mainly of stress 
management techniques may simply not be beneficial for addressing depressive symptoms in this 
group. Secondly, the observed positive association between stress management/negative symptoms 
and depressive symptoms may reflect increasing depressive symptoms: the clinician may respond by 
engaging more in stress management techniques.  
 
Limitations 
As this study was a secondary analysis of the Neurapro trial and was not specifically designed to 
evaluate CBCM, it comes with the clear limitations of no control group (i.e., a group who received no 
CBCM or a different form of psychotherapy). Furthermore, components were not randomly 
assigned, but selected on the basis of participant presentation. Although the current analytical 
approach reduced the possibility of reverse causation, we cannot ascertain cause and effect. That is, 
symptomatic levels may be impacted by CBCM, CBCM may be impacted by participant presentation, 
or both. Furthermore, it is likely that the different components may interact in impacting on 
symptomatic levels and there may be order effects of the specific CBCM components. Moreover, we 
were not able to investigate certain components (i.e., crisis management, family intervention) as 
these elements were delivered infrequently. However, our exploratory study can be used to 
generate hypotheses to be experimentally tested in the future. In light of psychotherapeutic 
interventions being a preferred option to medication in young people at risk of psychotic disorder, it 
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is important to identify the active ingredients or key components of CBT-informed therapies. 
Recommendations for future studies are dismantling studies or trials randomising participants to 
components. Furthermore, it is important to measure therapeutic alliance over the course of CBT 
intervention and capture the detailed subjective experience of the participants. Understanding the 
specific structure (e.g., duration) and content (components) of CBT that is most effective for 
symptoms in this patient group can critically inform future treatment.  
 
Conclusion 
Our findings indicate that the association between dose/content of CBCM and level of 
symptomatology in a sample of UHR participants depends on time in treatment and varies for 
depressive symptoms and APS. CBCM may positively impact depressive symptoms in the beginning 
of treatment, while APS may be positively impacted only later in the course of treatment, after an 
initial refractory phase. Therefore, it may be important to keep UHR young people engaged in 
treatment beyond this initial period and to increase awareness and validation of the potentially 
confronting and destabilising aspect of talking and discussing APS often for the first time. Future 
studies that randomise participants to CBCM or CBT components are needed to replicate the current 
findings and ascertain cause and effect. 
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Table 1. Components of cognitive-behavioural case management 
Components  % of sessions 
Included in analysis  
Monitoring  68.4 
Stress Management 51.3 
Assessment of symptoms 48.2 
Comorbidity 39.4 
Negative symptoms  38.8 
Homework 37.6 
Positive symptoms 30.3 
Case Management 21.7 
General Information/Psychoeducation 21.3 
Basic Symptoms 17.3 
  
Not included in analysis a  
Crisis Management 14.4 
Family Work 14.4 
Relapse Prevention and Termination 10.9 
  
  
a Excluded as these elements constituted less than 15% of the sessions 
 
 
Table 2.Baseline demographic and clinical data (N=242) 
Characteristic Mean (SD, Range) or N (%) 
 Age 18.9 (4.41, 13-37)  
Gender Female 130 (54%) 
Male 112 (46%) 
Ethnicity Caucasian 197 (81%) 
Black or African American 7 (3%) 
Asian 31 (13%) 
Other 7 (3 %) 
Education Primary school 90 (37%) 
Secondary school, discontinued 45 (19%) 
Secondary school, completed 66 (27%) 
Trade or technical training 26 (11%) 
Undergraduate university course 14 (6%) 
Missing 1 (0%) 
 APS 36.9 (17.04, 0-96) 
 MADRS 19.1 (8.87, 0-39)  
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Table 3. Results for the mixed model investigating the association between cognitive-behavioural case management 
component and level of attenuated positive symptom/level of depressive symptoms  
Component   Test statistic Adjusted Estimate (SE) [95% CI] for 
APS/MADRS per month 
APS    
Case Management x time 
(N=128) 
χ2(3) = 8.17, p = .043 M1: b = 1.87 (1.06) [-.22,3.96] 
M2: b = -1.59 (1.08)[-3.7,.54] 
M3: b = -1.68 (.88)[-3.40,.05]T 
M4: b = -2.01 (1.37)[-4.69,.67] 
Monitoring x time 
(N=211) 
χ2(3) = 19.23, p <.001 M1: b = 1.35 (.78) [-1.77,2.89] 
M2: b = -1.21 (.70) [-2.59, .17] 
M3: b = -1.27 (.66) [-2.56,.02]T 
M4: b = -.61 (.86) [-2.29,1.07] 
Assessment x time 
(N=193) 
χ2(3) = 14.65, p = .002 M1: b = 1.56 (.68) [.24,2.88]* 
M2: b = -.84 (.84) [-2.49,.80] 
M3: b = -1.31 (.86) [-3.00,.38] 
M4: b = -.79 (.86) [-2.48-.91] 
Stress Management x time  
(N=209) 
χ2(3) = 9.23, p = .026 M1: b = .93(.71) [-.46,2.32] 
M2: b = -1.34 (.80) [-2.91,.24] 
M3: b = -1.41 (.73) [-2.85, 0.22]T 
M4: b =-.50 (.84) [-2.15,1.15] 
Positive symptoms (N=156) b = 1.14 (.64) [-.13,2.40] N/A 
Homework (N=161) b= .31 (.66) [-.98,1.61] N/A 
MADRS    
Monitoring (N=211) b = .28(.31) [-.34,.90] N/A 
Assessment of symptoms 
(N=193) 
b = -.92 (.3 6) [-1.62,-.21]** N/A 
Stress Management (N=209) b = .66 (.27) [.13,1.19]* N/A 
Positive Symptoms (N=156) b =-.97 (.34) [-1.63,-.30]** N/A 
Negative Symptoms (N=174) b = 1.13 (.28) [.58,1.69]*** N/A 
Basic Symptoms (N=103) b = -.24 (.46) [-1.14,.67]  
Homework (N=161) b = .36 (.28) [-.18,.91] N/A 
***=p<.001; **=p<.01; *=p<.05; T=p<.057 
CBCM, cognitive-behavioural case management; APS, attenuated psychotic symptoms; 
MADRS=Montgomery-Asberg Depression Scale; M=Month  
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Figure legends 
Figure 1. Overview of the study protocol. CBCM, cognitive-behavioural case management; APS, 
attenuated psychotic symptoms; MADRS, Montgomery -Asberg Depression Scale.T0=Baseline, T1-T4 = 
Follow-up assessments 
Figure 2. Predicted values for APS for Month 1 and Month 3 for different CBCM dosing. The x-axis 
shows the number of CBCM sessions. The y-axis is the predictive margins. Statistics in Table 3. 
CBCM, cognitive-behavioural case management; APS, attenuated psychotic symptoms. 
 
